文献速递肺栓塞与肺血管病

利妥昔单抗B细胞清除治疗系统性硬化症相关肺动脉高压的安全性与疗效:多中心双盲随机安慰剂对照试验

Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

这项NIH资助的多中心双盲随机安慰剂对照概念验证试验纳入57例接受稳定标准治疗的SSc-PAH患者,比较利妥昔单抗与安慰剂。主要终点24周6MWD变化未达统计学显著性(23.6±11.1 m vs 0.5±9.7 m,P=0.12);纳入至48周数据后24周6MWD估计变化为25.5±8.8 m vs 0.4±7.4 m(P=0.03)。利妥昔单抗安全耐受良好,低RF、IL-12和IL-17水平可预测治疗反应。

要点

  • 24周主要终点6MWD变化未达统计学显著性。
  • 纳入48周数据后24周6MWD变化利于利妥昔单抗(P=0.03)。
  • 低RF、IL-12、IL-17水平可预测利妥昔单抗反应。

核心结论

  • B细胞清除治疗可能是SSc-PAH潜在有效且安全的辅助治疗。

研究设计与样本

  • NIH资助的多中心双盲随机安慰剂对照概念验证试验,57例接受稳定剂量标准治疗的SSc-PAH患者随机接受利妥昔单抗或安慰剂。
  • 利妥昔单抗组给予两次1,000 mg输注,间隔2周;主要终点为24周6MWD变化。

主要发现

  • 24周6MWD调整平均变化利妥昔单抗组23.6±11.1 m,安慰剂组0.5±9.7 m,P=0.12。
  • 纳入至48周数据后,24周6MWD估计变化利妥昔单抗组25.5±8.8 m,安慰剂组0.4±7.4 m,P=0.03。
  • 利妥昔单抗治疗安全且耐受良好。
  • 低RF、IL-12和IL-17水平作为利妥昔单抗反应的良好预测指标,ROC曲线下面积0.88-0.95。

关键数值与推荐

  • 主要终点24周6MWD变化未达统计学显著性(P=0.12)。
  • 纳入48周数据后24周6MWD变化P=0.03。
  • 低RF、IL-12、IL-17预测利妥昔单抗反应的ROC AUC为0.88-0.95。

临床怎么用

  • 利妥昔单抗可作为SSc-PAH的潜在辅助治疗,但主要终点未达统计学显著性,需进一步研究确认。
  • 低RF、IL-12、IL-17水平或可用于筛选可能从利妥昔单抗治疗中获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Systemic sclerosis (SSc)-pulmonary arterial hypertension (PAH) is one of the most prevalent and deadly forms of PAH. B cells may contribute to SSc pathogenesis. Objectives: We investigated the safety and efficacy of B-cell depletion for SSc-PAH. Methods: In an NIH-sponsored, multicenter, double-blinded, randomized, placebo-controlled, proof-of-concept trial, 57 patients with SSc-PAH on stable-dose standard medical therapy received two infusions of 1,000 mg rituximab or placebo administered 2 weeks apart. The primary outcome measure was the change in 6-minute-walk distance (6MWD) at 24 weeks. Secondary endpoints included safety and invasive hemodynamics. We applied a machine learning approach to predict drug responsiveness. Measurements and Main Results: We randomized 57 subjects from 2010 to 2018. In the primary analysis, using data through Week 24, the adjusted mean change in 6MWD at 24 weeks favored the treatment arm but did not reach statistical significance (23.6 ± 11.1 m vs. 0.5 ± 9.7 m; P = 0.12). Although a negative study, when data through Week 48 were also considered, the estimated change in 6MWD at Week 24 was 25.5 ± 8.8 m for rituximab and 0.4 ± 7.4 m for placebo (P = 0.03). Rituximab treatment appeared to be safe and well tolerated. Low levels of RF (rheumatoid factor), IL-12, and IL-17 were sensitive and specific as favorable predictors of a rituximab response as measured by an improved 6MWD (receiver operating characteristic area under the curve, 0.88-0.95). Conclusions: B-cell depletion therapy is a potentially effective and safe adjuvant treatment for SSc-PAH. Future studies in these patients can confirm whether the identified biomarkers predict rituximab responsiveness. Clinical trial registered with www.clinicaltrails.gov (NCT01086540).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Zamanian RT, Badesch D, Chung L, et al. Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med. 2021. PMID: 33651671. doi:10.1164/rccm.202009-3481OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。